Pliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Pliant Therapeutics, a clinical stage biotechnology company, will participate in the 20th Annual Needham Healthcare Conference from April 12-15, 2021. CEO Bernard Coulie will join a fireside chat with analyst Joseph Stringer on April 13, 2021, at 12:45 p.m. EDT. The event will be accessible via their website's Investors & Media page and will be available for 90 days. Pliant is focused on novel therapies for fibrosis, with candidates PLN-74809 and PLN-1474 in development for IPF, PSC, and liver fibrosis related to NASH.

SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 20^th Annual Needham Healthcare Conference to be held virtually from April 12 –15, 2021.

Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a fireside chat with Needham and Company’s senior biotech analyst, Joseph Stringer, on Tuesday, April 13, 2021 at 12:45 p.m. EDT / 9:45 a.m. PDT and, along with members of Pliant’s senior management team, will conduct one-on-one meetings with members of the investment community.

The live and archived event can be accessed by visiting the "News & Events" section of the "Investors & Media" page of the Pliant Therapeutics' website at www.pliantrx.com. The event will be available for 90 days.

About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of a_vß₆ and a_vß₁ integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of a_vß₁ for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook, and YouTube.

Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

What conference will Pliant Therapeutics participate in April 2021?

Pliant Therapeutics will participate in the 20th Annual Needham Healthcare Conference from April 12-15, 2021.

When is Bernard Coulie's fireside chat at the Needham Healthcare Conference?

Bernard Coulie's fireside chat is scheduled for April 13, 2021, at 12:45 p.m. EDT.

How can investors access Pliant Therapeutics' conference presentation?

Investors can access Pliant's presentation on the 'News & Events' section of their Investors & Media page at www.pliantrx.com.

What are Pliant Therapeutics' main product candidates?

Pliant's main product candidates are PLN-74809 for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and PLN-1474 for liver fibrosis associated with nonalcoholic steatohepatitis.

What is the significance of Orphan Drug Designation for PLN-74809?

PLN-74809 has received Orphan Drug Designation from the FDA for treating idiopathic pulmonary fibrosis and primary sclerosing cholangitis, highlighting its potential for rare disease treatment.